Shanghai Raas Revenue and Competitors

SHANGHAI,

Location

N/A

Total Funding

Estimated Revenue & Valuation

  • Shanghai Raas's estimated annual revenue is currently $14.3M per year.(i)
  • Shanghai Raas's estimated revenue per employee is $251,000

Employee Data

  • Shanghai Raas has 57 Employees.(i)
  • Shanghai Raas grew their employee count by -3% last year.

Shanghai Raas's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5M40-18%$10MN/A
#2
$24.8M9929%N/AN/A
#3
$84.1M0N/A$1.2MN/A
#4
$35.6M14230%N/AN/A
#5
$57.5M2296%N/AN/A
#6
$52.7M16825%$129.6MN/A
#7
$21.1M84-3%N/AN/A
#8
$61.2M244-13%N/AN/A
#9
$60.6M19320%$115.5MN/A
#10
$56.2M179-3%$122.9MN/A
Add Company

What Is Shanghai Raas?

Shanghai Raas Blood Products is a medical device company based out of SHANGHAI. Shanghai Raas Blood Products representatives, don't miss out on opportunities to build relationships with members on LinkedIn. Claim your page, write a simple description, and share content to attract followers that can lead to new customers, brand fans, and future employees. Go here to get started: http://linkd.in/1DUpBvu

keywords:N/A

N/A

Total Funding

57

Number of Employees

$14.3M

Revenue (est)

-3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Shanghai Raas News

2022-04-17 - Worldwide Plasma Derived Medicine Industry to 2028 ...

... CSL Limited, Bio Products Laboratory Ltd., China Biologic Products Holdings, Inc., Kedrion, Shanghai RAAS, ADMA Biologics Inc.,...

2022-04-17 - Tesla and other firms look to reopen Shanghai factories ...

Other companies that are preparing to reopen include biotechnology firm Shanghai Raas Blood Products and a unit of Shanghai Pharmaceuticals,...

2022-04-13 - Human Fibrinogen Market 2022 Industry Scenario – CSL ...

LFB Group; Shanghai RAAS Blood Products; Jiangxi Boya Bio-Pharmaceutical; Hualan Biological Engineering; Harbin Pacific Biopharmaceutical; GREEN...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$15M58-2%N/A
#2
$7.4M5959%N/A
#3
$13.7M605%N/A
#4
$318.4M61-5%N/A
#5
$7.4M63-3%N/A